Open Access

Malignant phyllodes tumor metastasized to the right ventricle: a case report

  • Fumi Yoshidaya1,
  • Naoki Hayashi1Email author,
  • Katsuhito Takahashi2,
  • Koyu Suzuki3,
  • Futoshi Akiyama4,
  • Mitsutomi Ishiyama5,
  • Yuko Takahashi1,
  • Atsushi Yoshida1,
  • Hiroshi Yagata1,
  • Seigo Nakamura1, 6,
  • Hiroko Tsunoda5 and
  • Hideko Yamauchi1
Surgical Case Reports20151:121

DOI: 10.1186/s40792-015-0121-6

Received: 8 September 2015

Accepted: 20 November 2015

Published: 5 December 2015

Abstract

Cardiac metastasis of malignant phyllodes tumor is very rare. We herein report a rare case that developed cardiac metastasis from malignant phyllodes tumor. A 38-year-old woman underwent lumpectomy, and the final pathological findings showed the 5-cm malignant phyllodes tumor partially containing 1 cm of squamous cell carcinoma. Four months after the first surgery, a local recurrence of malignant phyllodes tumor and distant metastases to the bone, lung, pulmonary main trunk, and right ventricle were detected. Mass reduction surgery of cardiac metastasis of the malignant phyllodes tumor was performed to avoid sudden death. In immunohistochemical findings, the tumor was suspected to be originated in myoepithelial cells because of the expression of smooth muscle lineage including α-smooth muscle actin and Calponin1 and highly malignant characteristics showing MIB-1 and p53 highly positive with angiogenesis. Further studies are needed to clarify the effective treatment to these tumors.

Keywords

Malignant phyllodes tumor Breast Cardiac metastasis Myoepithelial cells Debulking surgery

Background

Phyllodes tumor is a fibroepithelial neoplasm of the female breast which was classified as benign, borderline malignant, or malignant state, accounting for 0.5 % of all breast tumors [1]. Approximately 50 % of this tumor is benign, and 25 % is borderline [2]. However, it can recur locally in any state [3]. On the other hand, 16 to 30 % of phyllodes tumors were reported to be histologically malignant [4]. Surgical excision is the only effective treatment. Cardiac metastasis of phyllodes tumor is very rare and hard to manage. We herein report a rare case of a patient with a malignant phyllodes tumor that metastasized to the right ventricle and received cardiac surgery.

Case presentation

A 38-year-old woman visited our hospital with a firm mass in her left breast. The mass had increased in size in a few months. Ultrasounds showed an over 5-cm hypoechoic mass on lower inner quadrant of her left breast. It was diagnosed borderline phyllodes tumor by ultrasound-guided needle biopsy.

The patient underwent lumpectomy. Final pathological findings showed the malignant phyllodes tumor measured 5.0 × 4.7 × .4.0 cm, partially containing 1.0 × 0.9 cm of squamous cell carcinoma (SCC), pT1b N0 M0 stage I, stating that nuclear grade was 2, estrogen receptor was 6, and progesterone receptor was 0 by Allred score, and human epidermal growth factor receptor type2 (HER2) status was negative (Figs. 1 and 2). SCC was not included in the phyllodes tumor but partially contacted with the tumor by epithelial cells.
Fig. 1

The primary phyllodes tumor in the left breast had leaf-like architecture of epithelial cells and high-grade malignant stromal overgrowth (H&E, ×4 (a), magnificent). The tumor partially containing 1.0 × 0.9 cm SCC in the primary site: SCC partially have contact with epithelial cells of phyllodes tumor (H&E, ×4 (b), magnificent). AE1/3 was positive on SCC and negative on the phyllodes tumor (×10 (c), magnificent). H&E, hematoxylin and eosin; SCC, squamous cell carcinoma

Fig. 2

Autopsy specimen of the heart in macroscopic findings (a): Cardiac tumor was 10 × 7 × 7 cm, occupied 70 % of the right ventricle. Right ventricle (RV) was almost in stenosis. Spindle tumor cells with highly stromal overgrown involving the heart were similar to primary malignant tumor cells in the metastatic site (H&E, ×10 (b), magnificent)

Because of the margin-positive of phyllodes tumor and the hormone receptor-positive presence of SCC, an additional mastectomy and sentinel node biopsy were performed 1 month after the first surgery. Residual malignant phyllodes tumor was detected but SCC was not found on the surgical specimen. The patient started to receive tamoxifen for the hormone receptor-positive SCC in adjuvant setting.

Four months after the first surgery, she presented in our hospital a 1-month history of a breast tumor on her left chest wall, 1-week history of edema on her face and bilateral legs, dyspnea at rest, back pain, and declining of urine volume, all of which had progressively worsened in a few days. Her consciousness was clear and vital signs were normal, and The Eastern Cooperative Oncology Group performance status was 1. Physical examination revealed edema on bilateral feet and face that indicated congestive heart failure. Chest X-rays showed multiple lung metastasis, enlargement of cardiothoracic ratio (54 %), and protrusion of the left second arch showing pulmonary artery. Computed tomography scan revealed a local recurrence on the left breast, embolism to the right ventricle and pulmonary main trunk, bone destruction (fourth thoracic vertebrae, Th4), and lung metastasis. Transthoracic echocardiography showed a 5.8 × 4.1 × 7.0-cm mass with homogeneous echogenicity that occupied nearly the entire right ventricular (RV) cavity and almost obstructed RV outflow tract (RVOT). It also involved the pulmonary valve and extended to the pulmonary artery. The mass had invaded the RV septum to the endocardium and then grew forward to the RV reaching the pulmonary artery. There were a few evidences of pericardial effusions. We diagnosed a chest wall recurrence of malignant phyllodes tumor and distant metastases to the bone, lung, pulmonary main trunk, and right ventricle.

After multidisciplinary discussion among breast surgeon, medical oncologist, radiologist, cardiologist, and cardiac surgeon, the patient decided to undergo urgent mass reduction surgery releasing the severe stenosis of RVOT to avoid sudden death. The histological finding revealed a metastasis of malignant phyllodes tumor to right ventricle.

She was discharged from the hospital on the 12th postoperative day. However, on the 66th day after the cardiac surgery, she died from heart failure because of re-enlargement of the residual tumor in the right ventricle.

Pathological findings

Autopsy showed the presence of local recurrence and multiple distant metastases to the lung, bone (Th4), diaphragm, and cardiac ventricle of malignant phyllodes tumor (Fig. 3a). Spindle tumor cells involving the heart were similar to primary malignant tumor cells in microscopic findings (Fig. 3b). SCC was not involved in any metastatic sites. In immunohistochemical findings of primary tumor, pan-cytokeratin AE1/AE3 was negative on the phyllodes tumor site while positive on SCC site (Fig. 1d, e). The specimen of metastatic tumor to the right ventricle showed that pan-cytokeratin AE1/AE3 was negative, suggesting to be originated from the malignant phyllodes tumor. Markers suggesting differentiation to smooth muscle, α-smooth muscle actin, and Calponin1 were partially positive. CD44 was positive. MIB-1 was highly positive (≥  70 %), and p53 was strongly overexpressed. Angiogenesis in the tumor was frequently observed as demonstrated by high expression level of vascular endothelial growth factor receptor-2 (VEGFR2) (Flk-1) in tumor vessels.
Fig. 3

Histologic and immunohistochemical findings of metastatic tumor of the heart: formalin-fixed and paraffin-embedded slices were immunostained, a α-smooth muscle actin and b Calponin1, c tumor suppressor, p53, and d VEGFR2 (Flk-1). Bars indicate 100 μm

Discussion

Once patients with malignant phyllodes tumor developed metastasis, their prognosis is extremely poor. After the development of metastases, the mean overall survival is 30 months [5]. For phyllodes tumors, complete surgical resection with wide margins is the fundamental treatment to prevent metastasis [6,7]. Despite the complete surgical resection, local failure rates range between 20 and 30 % for malignant tumors [810].

Approximately 22 % of cases of malignant phyllodes tumor may give rise to hematogenous metastases. In a review of 67 patients who had metastatic phyllodes tumors, Kessinger and colleagues described the frequency of metastasis in each site: lungs (66 %), bones (28 %), heart (9 %), and liver (6 %).

In most cases, the metastases resemble to the sarcomatous component of the primary tumor [11]. The role of any adjuvant therapy, such as chemotherapy, hormonal therapy, and even radiotherapy remains unclear [12].

Cardiac metastasis of malignant phyllodes tumor is very rare. To our knowledge, there are only four cases that underwent cardiac surgery for the metastasis (Table 1) [1316].
Table 1

Cases that underwent cardiac surgery for metastasis

 

Age

Pre-operative general status

Surgery

Location of cardiac metastasis

Overall survival from the cardiac operation

Survival duration from initial surgery

Our case

38

Stable

Mass reduction of RV, PA

RV, PA

66 days

3 months

Garg et al. [13]

35

Cardiac shock

Mass reduction of RV

RV

8 days

3 years

Jackson et al. [14]

69

Unstable

Mass reduction of RV, PA

RV, PA

77 days

77 days

Myojin et al. [15]

47

Unstable

Mass reduction of RV, PA

Tricuspid valve plasty

RV, PA

15 days

3 months

Nakatsu et al. [16]

69

Stable

Mass reduction of LA

LA

1 year (still alive)

NA

LA left atrium, RV ventricle, PA pulmonary artery, NA not applicable

In four out of the five cases including our cases, tumors were metastasized to the right ventricle and one to the left atrium. In these cases, debulking surgery could avoid sudden death, although most cases had unstable condition after the surgery and showed poor prognosis. Surgery to cardiac metastasis has a chance to avoid sudden death and improve the patients’ quality of life and spend better the rest of their lives, regardless of how short and low the quality of their lives are even after the cardiac surgery. The patient strongly hoped to undergo the surgery to have a possibility to prolong her life with her children for a couple of months. After the surgery, her symptom of heart failure was decreased and she and her family could be satisfied to spend the rest of her life at her home.

In the current study, markers that were frequently observed in undifferentiated and high-grade sarcoma were shown in immunohistochemical findings of the specimen. The tumor was suspected to have been originated from myoepithelial cells because of the expression of smooth muscle lineage with Calponin1. Expression of basic calponin has proved not only to smooth muscle cells but also in cells with certain smooth muscle-like phenotypes including myofibroblasts, myoepthelial cells, leiomyosarcomas, synovial sarcomas, and a subset of osteosarcomas [17]. It also showed highly malignant characteristics evidenced by the presence of many cells suggesting high proliferation with highly positive MIB-1 and p53 expression. MIB-1 and p53 expression has been reported as a marker of aggressiveness in many tumors. In the phyllodes tumor, the expression level of p53, tumor angiogenesis, and MIB-1 have been described to reflect the degree of malignancy [18], although these are not correlated with their prognosis.

Belkacémi and colleagues reported that in 159 patients with malignant and borderline phyllodes tumor, radiotherapy significantly decreased local recurrence rate (p = 0.02) [20]. In a prospective study of 46 patients with borderline or malignant phyllodes tumor who underwent breast-conserving surgery with adjuvant radiotherapy, none of the 46 patients developed a local recurrence with a median follow-up of 56 months [19]. Although she did not receive irradiation therapy because of her predicted short prognosis, radiotherapy rather than chemotherapy in adjuvant setting may have a good potential for patients with malignant phyllodes tumor after surgical resection for local control and prevention of metastasis.

Conclusions

We experienced a rare case of malignant phyllodes tumor of the breast with high malignant characteristics that was originated from myoepithelial cells and developed cardiac metastasis shortly after the removal of the primary breast tumor. Our experience indicated that mass reduction surgery of cardiac metastasis of malignant phyllodes tumor might be an option for avoiding sudden death and improving patients’ quality of life, regardless of the extremely poor prognosis. Further large studies are needed to clarify the effective treatment to these tumors.

Abbreviations

HER2: 

human epidermal growth factor receptor type2

RV: 

right ventricle

RVOT: 

RV outflow tract

SCC: 

squamous cell carcinoma

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
Department of Breast Surgical Oncology, St. Luke’s International Hospital
(2)
Department of Molecular Medicine and Pathophysiology, Osaka Medical Center for Cancer and Cardiovascular Disease
(3)
Department of Diagnostic Pathology, St. Luke’s International Hospital
(4)
Division of Pathology, Cancer institute Hospital of Japanese Foundation for Cancer Research
(5)
Department of Radiology, St. Luke’s International Hospital
(6)
Department of Breast Surgical Oncology, Showa University School of Medicine

References

  1. Rowell MD, Perry RR, Hsiu JG, Barranco SC. Phyllodes tumors. Am J Surg. 1993;165:376–79.View ArticlePubMedGoogle Scholar
  2. Calhoun K, Lawton TJ, Kim JM. Phyllodes tumors. In: Diseases of the breast. In Harris J, Lippman ME, Osborne CK, M M (eds): Lippincott Williams and Wilkins. Philadelphia, 2010;781.Google Scholar
  3. Jones AM, Mitter R, Poulsom R, Gillett C, Hanby AM, Tomlinson IP, et al. mRNA expression profiling of phyllodes tumours of the breast: identification of genes important in the development of borderline and malignant phyllodes tumours. J Pathol. 2008;216:408–17.View ArticlePubMedGoogle Scholar
  4. Rosenfeld JC, DeLaurentis DA, Lerner H. Cystosarcoma phyllodes. Diagnosis and management. Cancer Clin Trials. 1981;4:187–93.PubMedGoogle Scholar
  5. Kessinger A, Foley JF, Lemon HM, Miller DM. Metastatic cystosarcoma phyllodes: a case report and review of the literature. J Surg Oncol. 1972;4:131–47.View ArticlePubMedGoogle Scholar
  6. Guillot E, Couturaud B, Reyal F, Curnier A, Ravinet J, Laé M, et al. Management of phyllodes breast tumors. Breast J. 2011;17:129–37.View ArticlePubMedGoogle Scholar
  7. Khosravi-Shahi P. Management of non metastatic phyllodes tumors of the breast: review of the literature. Surg Oncol. 2011;20:e143–48.View ArticlePubMedGoogle Scholar
  8. Ciatto S, Bonardi R, Cataliotti L, Cardona G. Phyllodes tumor of the breast: a multicenter series of 59 cases. Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer), Italy. Eur J Surg Oncol. 1992;18:545–49.PubMedGoogle Scholar
  9. Stebbing JF, Nash AG. Diagnosis and management of phyllodes tumour of the breast: experience of 33 cases at a specialist centre. Ann R Coll Surg Engl. 1995;77:181–4.PubMed CentralPubMedGoogle Scholar
  10. Zurrida S, Bartoli C, Galimberti V, Squicciarini P, Delledonne V, Veronesi P, et al. Which therapy for unexpected phyllode tumour of the breast? Eur J Cancer. 1992;28:654–57.View ArticlePubMedGoogle Scholar
  11. Moffat CJ, Pinder SE, Dixon AR, Elston CW, Blamey RW, Ellis IO. Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. Histopathology. 1995;27:205–18.View ArticlePubMedGoogle Scholar
  12. Telli ML, Horst KC, Guardino AE, Dirbas FM, Carlson RW. Phyllodes tumors of the breast: natural history, diagnosis, and treatment. J Natl Compr Canc Netw. 2007;5:324–30.PubMedGoogle Scholar
  13. Garg N, Moorthy N, Agrawal SK, Pandey S, Kumari N. Delayed cardiac metastasis from phyllodes breast tumor presenting as cardiogenic shock. Tex Heart Inst J. 2011;38:441–44.PubMed CentralPubMedGoogle Scholar
  14. Jackson CE, Gardner RS, Connelly DT. A novel approach for a novel combination: a trans-septal biopsy of left atrial mass in recurrent phyllodes tumour. Eur J Echocardiogr. 2009;10:171–72.View ArticlePubMedGoogle Scholar
  15. Myojin K, Murakami T, Ishii K, Kunihara T. An emergent operation for metastatic cardiac tumor of malignant cystosarcoma phyllodes. Jpn J Thorac Cardiovasc Surg. 1998;46:202–6.View ArticlePubMedGoogle Scholar
  16. Nakatsu T, Koshiji T, Sakakibara Y, Hagio K, Ishigami M, Arima Y, et al. Pulmonary artery obstruction due to a metastatic malignant phyllodes tumor of the breast. Gen Thorac Cardiovasc Surg. 2010;58:423–26.View ArticlePubMedGoogle Scholar
  17. Takahashi K, Yamamura H. Studies and perspectives of calponin in smooth muscle regulation and cancer gene therapy. Adv Biophys. 2003;37:91–111.View ArticlePubMedGoogle Scholar
  18. Tse GMK, Lui PCW, Scolyer RA, Putti TC, Kung FY, Law BK, et al. Tumour angiogenesis and p53 protein expression in mammary phyllodes tumors. Mod Pathol. 2003;16:1007–13.View ArticlePubMedGoogle Scholar
  19. Barth Jr RJ, Wells WA, Mitchell SE, Cole BF. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol. 2009;16:2288–94.View ArticlePubMedGoogle Scholar
  20. Belkacémi Y1, Bousquet G, Marsiglia H, Ray-Coquard I, Magné N, Malard Y, et al. Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys. 2008;70:492–500.Google Scholar

Copyright

© Yoshidaya et al. 2015